Search research articles
Contact Us
Filters
Showing results (81-90 of 224) with videos related to
Page
of 23
Sort By:
Critical Reviews in Oncology/Hematology
|
November 7, 2018
Corrigendum to "Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario" [Crit. Rev. Oncol./Hematol. 122 (February) (2018) 150-156]
Alfredo Addeo, Fabrizio Tabbò, Tim Robinson, et al.
Frontiers in Oncology
|
April 4, 2019
Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today?
Alex Friedlaender, Giuseppe Banna, Umberto Malapelle, et al.
Cancer
|
September 5, 2020
The METeoric rise of MET in lung cancer
Alex Friedlaender, Alexander Drilon, Giuseppe Luigi Banna, et al.
Current Oncology Reports
|
May 30, 2023
Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer
Jay Parekh, Kaushal Parikh, Joshua E Reuss, et al.
Journal of Thoracic Disease
|
April 15, 2024
The value of high-risk clinicopathologic features for chemotherapy in stage I non-small cell lung cancer: a propensity score-matched study
Kun Luan, Alfredo Addeo, Raja M Flores, et al.
Biomarker Research
|
February 12, 2024
Oncogenic alterations in advanced NSCLC: a molecular super-highway
Alex Friedlaender, Maurice Perol, Giuseppe Luigi Banna, et al.
Frontiers in Oncology
|
April 19, 2021
The Impact of Variant Allele Frequency in EGFR Mutated NSCLC Patients on Targeted Therapy
Alex Friedlaender, Petros Tsantoulis, Mathieu Chevallier, et al.
Frontiers in Oncology
|
October 31, 2025
Case Report: Trametinib in the treatment of patients with metastatic lung adenocarcinoma harboring <i>NF1</i> mutation: a case series and literature review
Floryane Kim, Maxime Borgeaud, Claudio De Vito, et al.
Cancer Treatment Reviews
|
February 17, 2020
KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures
Alex Friedlaender, Alexander Drilon, Glen J Weiss, et al.
Frontiers in Oncology
|
March 3, 2020
Tissue-Plasma TMB Comparison and Plasma TMB Monitoring in Patients With Metastatic Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors
Alex Friedlaender, Thierry Nouspikel, Yann Christinat, et al.
Page
of 23
Search research articles
Search
Showing results (81-90 of 224) with videos related to
Sort By:
Page
of 23
Critical Reviews in Oncology/Hematology
|
November 7, 2018
Corrigendum to "Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario" [Crit. Rev. Oncol./Hematol. 122 (February) (2018) 150-156]
Alfredo Addeo, Fabrizio Tabbò, Tim Robinson, et al.
Frontiers in Oncology
|
April 4, 2019
Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today?
Alex Friedlaender, Giuseppe Banna, Umberto Malapelle, et al.
Cancer
|
September 5, 2020
The METeoric rise of MET in lung cancer
Alex Friedlaender, Alexander Drilon, Giuseppe Luigi Banna, et al.
Current Oncology Reports
|
May 30, 2023
Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer
Jay Parekh, Kaushal Parikh, Joshua E Reuss, et al.
Journal of Thoracic Disease
|
April 15, 2024
The value of high-risk clinicopathologic features for chemotherapy in stage I non-small cell lung cancer: a propensity score-matched study
Kun Luan, Alfredo Addeo, Raja M Flores, et al.
Biomarker Research
|
February 12, 2024
Oncogenic alterations in advanced NSCLC: a molecular super-highway
Alex Friedlaender, Maurice Perol, Giuseppe Luigi Banna, et al.
Frontiers in Oncology
|
April 19, 2021
The Impact of Variant Allele Frequency in EGFR Mutated NSCLC Patients on Targeted Therapy
Alex Friedlaender, Petros Tsantoulis, Mathieu Chevallier, et al.
Frontiers in Oncology
|
October 31, 2025
Case Report: Trametinib in the treatment of patients with metastatic lung adenocarcinoma harboring <i>NF1</i> mutation: a case series and literature review
Floryane Kim, Maxime Borgeaud, Claudio De Vito, et al.
Cancer Treatment Reviews
|
February 17, 2020
KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures
Alex Friedlaender, Alexander Drilon, Glen J Weiss, et al.
Frontiers in Oncology
|
March 3, 2020
Tissue-Plasma TMB Comparison and Plasma TMB Monitoring in Patients With Metastatic Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors
Alex Friedlaender, Thierry Nouspikel, Yann Christinat, et al.
Page
of 23